Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda’s type 2 diabetes treatment approved

Takeda’s type 2 diabetes treatment approved

15th May 2009

Takeda has received authorisation for a treatment to help people with type 2 diabetes.

Actoplus met XR (pioglitazone HCl and metformin HCl extended release) works by targeting insulin resistance and is intended to be an addition to the patient’s diet and exercise regime.

The Food and Drug Administration has now approved the medication for adults with the condition who have insufficient glycemic control if they take Actos or metformin separately.

“Actoplus met XR is the first and only prescription oral antidiabetic fixed-dose combination medication available with the extended-release form of metformin ? in a convenient, once-daily dosing option,” explained the company.

The drug ? which is expected to be available later this year – was developed by Watson Laboratories and is licensed to Takeda.

Last month, Takeda discontinued clinical development of its TAK-379 compound.

It was being examined to see how effective it could manage and aid diabetes, but the company concluded the results did not meet the internal criteria to support further developments.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.